BioSpace News Archive

Infixion Bioscience, a pre-clinical drug discovery company focused on developing gene-targeted therapeutics for the rare genetic disorder Neurofibromatosis Type 1 (NF1), announced today the awarding of its third NIH SBIR Phase 1 grant from the National Institute of Neurological Disorders and Stroke (NINDS).

Atriva Therapeutics GmbH, a biopharmaceutical company that is pioneering the development of host-targeting antiviral therapies, announced today the topline findings from the Proof on Concept (POC) / Phase 2a RESPIRE study (zapnometinib) in patients hospitalized with moderate-to-severe COVID-19.

SiSaf Ltd, an RNA delivery and therapeutics company, is pleased to announce its autumn conference schedule for September and October.

Hoag’s Pickup Family Neurosciences Institute is initiating a clinical trial for a promising new investigational treatment for Alzheimer’s disease (AD).

Amare Global, The Mental Wellness Company, announced today the acquisition of Kyäni, Inc., a globally recognized and respected pioneer in health and wellness with business operations in over 50 countries.

For the past several months, the U.S. Food and Drug Administration has been working around the clock with our U.S. government partners, including the U.S. Department of Health and Human Services and the U.S. Department of Agriculture, to expand consumer access to infant formula products, while also ensuring that these products meet the agency’s safety, nutrition and quality standards.

In May 2022, FDA Commissioner Robert M. Califf, M.D., asked that I conduct an internal agency review of the agency’s actions related to multiple reports of Cronobacter illness in infants, the Abbott’s infant formula manufacturing plant in Sturgis, Michigan, and confounding issues that led to a shortage of infant formulas.

William McKeon, President and CEO of Texas Medical Center, shared plans for the continued strategic growth of the Texas Medical Center at the annual State of the TMC, hosted by the Greater Houston Partnership.

HAVN Life Sciences Inc. announces that the board of directors of the Company, on the advice of the Company’s Chief Financial Officer, has determined that the Company is no longer a going concern as it is unable to meet its financial obligations as they come due.

HTG Molecular Diagnostics, Inc. announced that the Fundación Instituto Valenciano de Oncología, located in Valencia, Spain, with its partners, the Fundación Pública Andaluza Progreso y Salud and the Centro de Investigación Biomédica en Red, have developed a laboratory-developed test for the assessment of breast cancer recurrence based on their use of the HTG EdgeSeq™ technology.